Projekte

Laufende Forschungsprojekte, die auf SCQM-Daten basieren

Mit unseren Daten unterstützen wir die Forschung im Bereich entzündlich-rheumatischer Erkrankungen. Eine Übersicht über die laufenden Forschungsprojekte finden Sie hier.

Wenn Sie mehr über ein laufendes Projekt erfahren möchten, wenden Sie sich bitte an unsere Leitung Wissenschaft, Catherine Raptis.

Projektnummer Titel Projektleiter
2024_13 A comparative cohort analysis of the time to treatment discontinuation and of the effectiveness of upadacitinib and tumor necrosis factor inhibitors in patients with rheumatoid arthritis: analysis of pooled data from RHUMADATA-OBRI-SCQM registries Axel Finckh, Denis Chocquette
2024_11 Description of the different switching patterns involving biologics (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs), and evaluation of their effectiveness in axSpA and PsA: results from the EuroSpA Research collaboration Network. Adrian Ciurea, USZ
2024_10 Comparison of structural damage and damage progression on MRI and conventional radiography of the spine in axial spondyloarthritis Adrian Ciurea, USZ
2024_02 Difficult-to-Manage (D2M) and treatment-refractory axial spondyloarthritis: Characterization and treatment outcomes Adrian Ciurea, USZ
2023_27 Differences of serum CHI3L1 and CHI3L2 in inflammatory arthritides and exploratory analysis of the prognostic value in rheumatoid arthritis Raphael Micheroli, Caroline Ospelt
2023_25 Is peripheral joint response to IL-17 inhibition in the spondyloarthritides site-specific? A European cohort study in psoriatic arthritis and axial spondyloarthritis Adrian Ciurea, USZ
2023_24 Validity and reliability of the Disease Activity index for Psoriatic Arthritis (DAPSA) and DAPSA-28 in European patients with Psoriatic Arthritis (PsA) Michael Nissen
2023_17 Comparison of DAS 28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index)/ SDAI (Simplified Disease Activity Index) scores: Which score better assesses remission or low disease activity (LDA) in patients with rheumatoid arthritis? Rüdiger Müller
2023_13 A comparative cohort analysis of the time to treatment discontinuation and of the effectiveness of upadacitinib and tumor necrosis factor inhibitors in patients with rheumatoid arthritis: analysis of pooled data from RHUMADATA-OBRI-SCQM registries. Denis Choquette, Axel Finckh, Claire Bombardier
2023_10 The role of the kynurenine pathway in regulating macrophage function in rheumatoid arthritis Bojana Müller, Universitätsspital Basel
2023_07 Digital Biomarker for Monitoring and Predicting Disease Severity in the Daily Lives of Rheumatoid Arthritis Patients Raphael Micheroli, USZ
2023_05 Early axial spondyloarthritis: Characterization, response to treatment and spinal radiographic progression in early vs. late disease Adrian Ciurea, USZ
2023_04 Cross-country differences in bDMARD prescription behaviour: associations between socioeconomics, real world bDMARD use and disease outcomes Delphine Courvoisier, HUG
2023_03 Therapeutic drug monitoring of JAK inhibitors as novel precision medicine instrument for acute and chronic inflammatory disorders François Girardin
2022_26 Occurrence and pattern of MRI and radiographic involvement of sacroiliac joints and spine in a European cohort of real-life patients with psoriatic arthritis Adrian Ciurea, USZ
2022_22 The MRI equivalent to modified New York criteria-positivity on conventional radiography of the sacroiliac joints Adrian Ciurea, USZ
2022_21 Cohort profile: the SCQM polymyalgia rheumatica and giant cell arteritis cohort Thomas Daikeler
2022_18 The association between MRI sacroiliac joint and spine inflammation and structural lesions, physical function and spinal mobility, and other outcome measures Adrian Ciurea, USZ
2022_17 Mechanistic modelling-based prediction of humoral vaccine responses in immuno-modulated patients with inflammatory rheumatic diseases after mRNA COVID-19 vaccination Christoph Berger, Andrea Rubbert-Roth
2022_16 Chondrocalcinosis in Rheumatoid Arthritis: an imaging analysis on correlation with disease activity and radiographic progression of Osteoarthritis Tobias Manigold, Thomas Hügle
2022_15 Explore the incidence of adverse events in patients treated with conventional and/or biological DMARDs Michael Nissen
2022_14 Explore the impact of selected comorbidities and extraarticular manifestations on prescription patterns and treatment effectiveness Michael Nissen
2022_11 Automated Dorsal Finger Fold Pattern Recognition on Real World Hand Photos as a Potential Digital Biomarker for the activity of Rheumatoid Arthritis Thomas Hugle
2022_09 EuroSpA area E: Data mapping survey study Michael Nissen
2022_08 Investigation of ASDAS-ESR cut-offs values for disease activity states in axial spondyloarthritis Adrian Ciurea, USZ
2022_07 Comparison of damage progression on MRI and conventional radiography of the sacroiliac joints in axial spondyloarthritis Raphael Micheroli, USZ
2022_06 Local vs. central readings of MRIs of the sacroiliac joints in patients with axial spondyloarthritis: investigation of agreement and the need for educational activities for local interpreters” for your information Adrian Ciurea, USZ
2022_05 Distribution of sacroiliac joint and spine imaging findings in a large cohort of real-life patients with axial SpA Adrian Ciurea, USZ
2022_04 Progression of sacroiliac joint and spinal structural changes in a European cohort of real-life patients with axial spondyloarthritis and psoriatic arthritis: A longitudinal analysis of magnetic resonance and X-ray images. Adrian Ciurea, USZ
2022_01 Gender-attributable differences in patient reported outcome measures in axial spondyloarthritis. Raphael Micheroli
2021_15 Ultrasonographic differences of synovitis grade between joint locations in rheumatoid arthritis Raphael Micheroli
2021_14 Impact of work-related physical stress on the response to different biologics in psoriatic arthritis Raphael Micheroli
2021_13 Impact of the Covid-19 pandemic on patient selection and treatment outcomes in spondyloarthritis patients treated with b/tsDMARDs across Europe Kim Lauper
2021_11 Treatment retention in SpA patients assessed with methods for interval- censored time-to-event data Myriam Riek, Seraphina Kissling, Adrian Ciurea
2021_07 Impact of national treatment guidelines, schedules of reimbursement and gross domestic product on treatment outcomes in patients treated with b/tsDMARDs across European observational spondyloarthritis registries Adrian Ciurea
2021_05 Understanding the impact of COVID-19 on the anti-apoA-1 IgG response in inflammatory rheumatism disorders Nicolas Vuilleumier, Axel Finckh
2021_04 Understanding the heterogeneity in patient populations across EuroSpA registries - the role of national access and treatment guidelines Michael Nissen
2021_03 Patient reported outcomes, drug adherence and clinical effectiveness of secukinumab in patients with psoriatic arthritis and axial spondylarthritis up to24 months: Results from the EuroSpA collaboration. Burkhard Möller
2021_02 Is uveitis associated with a more severe axial disease phenotype in axial spondyloarthritis? Adrian Ciurea
2021_01 Investigating drug-induced Chronic Kidney Disease using a pharmacogenomics approach in a multicentric framework Project Alexander Leichtle, Burkhard Möller
2020_20 Treatment of peripheral arthritis in the spondyloarthritides: Joint-specific response to TNF inhibitors? Adrian Ciurea
2020_19 Enthesitis in psoriatic arthritis and axial spondyloarthritis: Pattern, risk factors, and effectiveness of tumor necrosis factor inhibitors - A EuroSpA collaboration study Michael Nissen
2020_17 Real-world dynamics of anti-S1-binding antibodies after COVID-19 vaccination in patients with inflammatory rheumatic diseases Andrea Rubbert-Roth, Axel Finckh
2020_11 EuroSpA-D: Handling of missing component values in patient-reported outcomes Stylianos Georgiadis, Myriam Riek, Swiss PI (Michael Nissen)
2020_09 Vaccination in patients with rheumatic diseases Kim Lauper
2020_06 Psoriasis and Axial Involvement in Spondyloarthritis Adrian Ciurea
2020_04 Effectiveness of Abatacept and alternative biologic antirheumatic agents according to the shared epitope: The EASE study Axel Finckh
2020_03 Risk factors of infection with SARS-CoV-2 and of a serious course of COVID-19 in inflammatory rheumatic diseases in Switzerland Axel Finckh
2020_02 The effectiveness of a therapeutic change in RA patients with radiographic progression despite low disease activity Ruediger Mueller, Lena Brandt
2020_01 Prediction of erosions in RA by different modifications of the standard SONAR score Burkhard Moeller
2019_22 Response tolerance measures in rheumatology Myriam Riek
2019_18 SONAR SpA Validation study Michael Nissen, Pascal Zufferey
2019_16 Predictors for loss of productivity and the effect of b/tsDMARD treatment on loss of productivity in Swiss patients with rheumatoid arthritis Diego Kyburz
2019_13 Development of a prediction score for response to biological or targeted synthetic DMARDs in patients with inflammatory rheumatic diseases by combining clinical and -omics data Britta Maurer, Caroline Ospelt
2019_11 European collaborative analysis of real-world effectiveness of JAKinhibs versus anti-TNF agents and other bDMARDs (Jak-pot) Kim Lauper, HUG
2019_10 Gender differences in Biologicals and targeted synthetic Disease Modifying Anti-Rheumatic Drugs in Spondyloarthritis and psoriatic arthritis Michael Nissen, Adrian Ciurea, Burkhard Moeller
2019_08 SYSCID: Discovering new biomarkers by large “multi-omics” analysis to identify individuals in pre-clinical stages of Rheumatoid Arthritis C. Lamacchia, Axel Finckh
2019_04 Multimodal-based disease activity indices und risk of progression in rheumatoid arthritis Giorgio Tamborrini (now Pascal Zufferey), P. Mandl
2018_16 Comparative efficacy of TNF-inhibitors (TNFi) versus other mode of action (OMA) biological DMARDs in PsA -- an observational study Burkhard Moeller
2018_07 Translating humoral immunity against apolipoprotein A1 from an emerging CV risk factor to cardiovascular risk stratification tool in IRD Cem Gabay, Nicolas Vuilleumier
2018_03 Retention and effectiveness of TNF inhibitor treatment in axial spondyloarthritis and psoriatic arthritis: an analysis from the EuroSpA collaboration Michael Nissen, Adrian Ciurea, Cem Gabay, Burkhard Moeller
2018_02 Patient reported outcomes in patients with axial spondyloarthritis and psoriatic arthritis starting treatment with TNF inhibitors: an analysis from the EuroSpA collaboration Michael Nissen, Adrian Ciurea, Cem Gabay, Burkhard Moeller
2017_08 COmPASS II weather sensitivity Ulrich Walker
2015_09 Analysis of fine anti-citrullinated peptide antibody specificities, anti-carbamylated peptide antibodies and genetic characteristics in psoriatic arthritis patients Michael Nissen
2015_03 Impact of axSpA on work participation and the role of anti-TNF treatment Adrian Ciurea
2014_08 The effect of body mass index on the course of disease activity in axial spondyloarthritis Adrian Ciurea, Raphael Micheroli
2014_05 Regular exercise and functional outcomes in axial spondyloarthritis Adrian Ciurea, Mauro Bachmann

Internationale Kooperationsprojekte sind nur zur Information aufgeführt. Bitte beachten Sie, dass die Aufnahme weiterer Mitarbeitenden in internationalen Projekten oft nicht möglich, da Grösse der Projektgruppe pro Land beschränkt ist.